CONMED Q3 Earnings Call Highlights

CONMED NYSE: CNMD reported third-quarter 2026 revenue of $335.6 million, with organic constant-currency sales growth of 6.7% as the medical technology company cited broad-based contributions from its general surgery and orthopedic surgery businesses.

MarketBeat • a day ago

CONMED Corporation (CNMD) Q3 2026 Earnings Call Transcript

CONMED Corporation ( CNMD ) Q3 2026 Earnings Call October 28, 2026 4:30 PM EDT Company Participants Patrick Beyer - President, CEO & Director John Gallagher - Executive VP, CFO and Principal Financial & Accounting Officer Conference Call Participants Anton Heldmann - BMO Capital Markets Equity Research Ross Osborn - Wells Fargo Securities, LLC, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Michael Matson - Needham & Company, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - BofA Securities, Research Division Young Li - Jefferies LLC, Research Division Presentation Operator Hello, and welcome to CONMED's Third Quarter of 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

Seeking Alpha • a day ago

CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the third quarter ended September 30, 2026 and updated its financial guidance for the full year ending 2026. Third Quarter 2026 Highlights(1) Sales of $335.6 million decreased 0.7% year-over-year as reported and decreased 0.8% on a constant currency(2) basis. Excluding the impact of the Company's previously announced strategic exits of GI product offerings, net sales increased 6.7% on an organic c.

Business Wire • Oct 28, 2026

Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings

While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Oct 29, 2026

Conmed (CNMD) Q3 Earnings Top Estimates

Conmed (CNMD) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $1.08 per share a year ago.

Zacks Investment Research • Oct 29, 2026

CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode. This confer.

Business Wire • Oct 1, 2026

Harbor SMID Cap Value ETF Q2 2026 Contributors And Detractors

In Q2 2026, the Harbor SMID Cap Value ETF returned 22.76%, outperforming its benchmark, the Russell 2500 Value Index, which returned 18.50%. Contributing to performance was Albany International, whose shares gained 43% during the quarter following better-than-expected operating results and continued strength in its aerospace and defense businesses. Another contributor to performance was BorgWarner, whose shares gained 23% during the quarter following better-than-expected first quarter results and growing investor optimism around the company's long-term growth opportunities.

Seeking Alpha • Sep 19, 2026

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CONMED's BioBrace and AirSeal platforms, robotic growth and easing supply bottlenecks support its long-term outlook despite tariff headwinds.

Zacks Investment Research • Sep 16, 2026

Harbor Small Cap Value Fund Q2 2026 Contributors And Detractors

The Harbor Small Cap Value Fund returned 21.09%, outperforming the Russell 2000 Value Index, which returned 17.19%, net of fees, during Q2 2026. Contributing to performance was Albany International Corp., a manufacturer of specialized engineered materials serving the paper production and aerospace industries. We made no purchases or sales in the second quarter of 2026.

Seeking Alpha • Sep 8, 2026

Conmed (CNMD) Up 7.1% Since Last Earnings Report: Can It Continue?

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Aug 28, 2026